Alterity Therapeutics Ltd (ATHE) - Net Assets
Based on the latest financial reports, Alterity Therapeutics Ltd (ATHE) has net assets worth $54.21 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($56.86 Million) and total liabilities ($2.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ATHE financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $54.21 Million |
| % of Total Assets | 95.34% |
| Annual Growth Rate | N/A |
| 5-Year Change | 39.16% |
| 10-Year Change | 35.18% |
| Growth Volatility | 80.58 |
Alterity Therapeutics Ltd - Net Assets Trend (1998–2025)
This chart illustrates how Alterity Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore ATHE asset base for the complete picture of this company's asset base.
Annual Net Assets for Alterity Therapeutics Ltd (1998–2025)
The table below shows the annual net assets of Alterity Therapeutics Ltd from 1998 to 2025. For live valuation and market cap data, see Alterity Therapeutics Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $42.40 Million | +207.31% |
| 2024-06-30 | $13.80 Million | -39.52% |
| 2023-06-30 | $22.81 Million | -35.68% |
| 2022-06-30 | $35.47 Million | +16.40% |
| 2021-06-30 | $30.47 Million | +188.88% |
| 2020-06-30 | $10.55 Million | -36.28% |
| 2019-06-30 | $16.55 Million | +2.95% |
| 2018-06-30 | $16.08 Million | -32.12% |
| 2017-06-30 | $23.69 Million | -24.48% |
| 2016-06-30 | $31.37 Million | -19.80% |
| 2015-06-30 | $39.11 Million | +3.79% |
| 2014-06-30 | $37.69 Million | +169.67% |
| 2013-06-30 | $13.97 Million | +148.51% |
| 2012-06-30 | $5.62 Million | -18.87% |
| 2011-06-30 | $6.93 Million | +32.55% |
| 2010-06-30 | $5.23 Million | +39.46% |
| 2009-06-30 | $3.75 Million | -62.08% |
| 2008-06-30 | $9.89 Million | +76.22% |
| 2007-06-30 | $5.61 Million | -35.76% |
| 2006-06-30 | $8.73 Million | -55.24% |
| 2005-06-30 | $19.51 Million | -49.27% |
| 2004-06-30 | $38.47 Million | +143.82% |
| 2003-06-30 | $15.78 Million | -5.40% |
| 2002-06-30 | $16.68 Million | -22.04% |
| 2001-06-30 | $21.39 Million | +3.20% |
| 2000-06-30 | $20.73 Million | +25796.43% |
| 1999-06-30 | $-80.67K | -11940.30% |
| 1998-06-30 | $-670.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alterity Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22588868000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $262.95 Million | 620.12% |
| Other Comprehensive Income | $5.34 Million | 12.60% |
| Total Equity | $42.40 Million | 100.00% |
Alterity Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Alterity Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vivid Seats Inc
NASDAQ:SEAT
|
$72.72 Million |
|
Panin Sekuritas Tbk
JK:PANS
|
$72.74 Million |
|
Muda Holdings Bhd
KLSE:3883
|
$72.76 Million |
|
Miko NV
BR:MIKO
|
$72.78 Million |
|
Bookook Securities Co Ltd
KO:001275
|
$72.71 Million |
|
Korea Business News Co. Ltd
KQ:039340
|
$72.70 Million |
|
High Co. SA
PA:HCO
|
$72.69 Million |
|
PannErgy Nyrt.
F:PPL
|
$72.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alterity Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,798,057 to 42,403,086, a change of 28,605,029 (207.3%).
- Net loss of 12,147,828 reduced equity.
- New share issuances of 42,570,645 increased equity.
- Other comprehensive income increased equity by 536,101.
- Other factors decreased equity by 2,353,889.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.15 Million | -28.65% |
| Share Issuances | $42.57 Million | +100.4% |
| Other Comprehensive Income | $536.10K | +1.26% |
| Other Changes | $-2.35 Million | -5.55% |
| Total Change | $- | 207.31% |
Book Value vs Market Value Analysis
This analysis compares Alterity Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.19x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-06-30 | $-0.01 | $4.73 | x |
| 1999-06-30 | $-1.05 | $4.73 | x |
| 2000-06-30 | $375.11 | $4.73 | x |
| 2001-06-30 | $248.10 | $4.73 | x |
| 2002-06-30 | $183.04 | $4.73 | x |
| 2003-06-30 | $164.89 | $4.73 | x |
| 2004-06-30 | $314.08 | $4.73 | x |
| 2005-06-30 | $95.38 | $4.73 | x |
| 2006-06-30 | $40.93 | $4.73 | x |
| 2007-06-30 | $23.92 | $4.73 | x |
| 2008-06-30 | $33.96 | $4.73 | x |
| 2009-06-30 | $11.12 | $4.73 | x |
| 2010-06-30 | $13.79 | $4.73 | x |
| 2011-06-30 | $16.80 | $4.73 | x |
| 2012-06-30 | $11.73 | $4.73 | x |
| 2013-06-30 | $24.76 | $4.73 | x |
| 2014-06-30 | $52.83 | $4.73 | x |
| 2015-06-30 | $46.68 | $4.73 | x |
| 2016-06-30 | $35.25 | $4.73 | x |
| 2017-06-30 | $26.62 | $4.73 | x |
| 2018-06-30 | $18.07 | $4.73 | x |
| 2019-06-30 | $16.13 | $4.73 | x |
| 2020-06-30 | $7.07 | $4.73 | x |
| 2021-06-30 | $10.77 | $4.73 | x |
| 2022-06-30 | $8.85 | $4.73 | x |
| 2023-06-30 | $5.64 | $4.73 | x |
| 2024-06-30 | $2.27 | $4.73 | x |
| 2025-06-30 | $3.98 | $4.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alterity Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -223.35%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.09x
- Recent ROE (-28.65%) is above the historical average (-67.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 0.00% | 0.00% | 0.00x | 0.00x | $-623.00 |
| 1999 | 0.00% | 0.00% | 0.00x | 0.00x | $-71.93K |
| 2000 | -6.40% | -1684.00% | 0.00x | 1.01x | $-3.40 Million |
| 2001 | -19.35% | -801.84% | 0.02x | 1.04x | $-6.28 Million |
| 2002 | -32.69% | -686.23% | 0.05x | 1.05x | $-7.12 Million |
| 2003 | -28.97% | -252.40% | 0.11x | 1.04x | $-6.15 Million |
| 2004 | -25.54% | -425.88% | 0.06x | 1.07x | $-13.67 Million |
| 2005 | -127.63% | -942.61% | 0.12x | 1.14x | $-26.86 Million |
| 2006 | -134.25% | -1537.92% | 0.07x | 1.19x | $-12.60 Million |
| 2007 | -198.54% | -2197.05% | 0.07x | 1.38x | $-11.70 Million |
| 2008 | -137.44% | -2762.17% | 0.04x | 1.19x | $-14.58 Million |
| 2009 | -200.62% | -1756.87% | 0.09x | 1.23x | $-7.90 Million |
| 2010 | -93.83% | -2282.20% | 0.03x | 1.30x | $-5.43 Million |
| 2011 | -92.79% | -4118.99% | 0.02x | 1.30x | $-7.12 Million |
| 2012 | -93.17% | -2806.90% | 0.03x | 1.31x | $-5.80 Million |
| 2013 | -55.72% | -5161.66% | 0.01x | 1.22x | $-9.18 Million |
| 2014 | -35.37% | -3664.14% | 0.01x | 1.10x | $-17.10 Million |
| 2015 | -15.05% | -3327.87% | 0.00x | 1.07x | $-9.80 Million |
| 2016 | -24.64% | -5418.28% | 0.00x | 1.08x | $-10.87 Million |
| 2017 | -31.84% | -5696.60% | 0.01x | 1.07x | $-9.91 Million |
| 2018 | -51.40% | -4108.75% | 0.01x | 1.16x | $-9.87 Million |
| 2019 | -72.26% | -11020.84% | 0.01x | 1.20x | $-13.62 Million |
| 2020 | -95.37% | -2444.24% | 0.03x | 1.26x | $-11.11 Million |
| 2021 | -50.24% | -352.78% | 0.13x | 1.10x | $-18.36 Million |
| 2022 | -36.22% | -250.75% | 0.12x | 1.17x | $-16.39 Million |
| 2023 | -60.52% | -352.54% | 0.14x | 1.20x | $-16.09 Million |
| 2024 | -138.60% | -475.79% | 0.21x | 1.39x | $-20.50 Million |
| 2025 | -28.65% | -223.35% | 0.12x | 1.09x | $-16.39 Million |
Industry Comparison
This section compares Alterity Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alterity Therapeutics Ltd (ATHE) | $54.21 Million | 0.00% | 0.05x | $72.71 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more